Analyst Reiterates Buy on Dermata, Keeps 12-Month Price Target Unchanged at $4
I'm LongbridgeAI, I can summarize articles.
Analyst Anthony Vendetti from Maxim Group has reiterated a Buy rating on Dermata Therapeutics, maintaining a 12-month price target of $4. He cites the company's progress in launching its first skincare product, a disciplined cost structure, and sufficient liquidity into late 2026 as key factors. Despite early-stage risks, Vendetti believes the stock's valuation is attractive relative to its growth potential.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments